Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,090,200 | 2,488,200 | 2,011,800 | 1,920,700 | 2,602,000 |
| Marketable Securities | 5,259,200 | 6,524,300 | 7,784,700 | 7,888,300 | 7,917,500 |
| Receivables | 5,561,000 | 6,211,900 | 6,107,100 | 5,717,100 | 5,222,200 |
| Inventories | 3,192,400 | 3,087,300 | 3,018,000 | 2,873,600 | 2,714,900 |
| TOTAL | $17,571,700 | $18,660,900 | $19,333,600 | $19,081,600 | $18,871,500 |
| Non-Current Assets | |||||
| PPE Net | 4,694,200 | 4,599,700 | 4,439,200 | 4,305,900 | 4,225,500 |
| Investments And Advances | 9,276,300 | 8,900,100 | 8,490,900 | 7,722,400 | 6,978,800 |
| Intangibles | 1,167,000 | 1,148,600 | 1,120,100 | 1,102,200 | 1,058,700 |
| Other Non-Current Assets | 4,836,000 | 4,450,100 | 4,058,100 | 3,874,700 | 3,235,100 |
| TOTAL | $19,973,500 | $19,098,500 | $18,108,300 | $17,005,200 | $15,498,100 |
| Total Assets | $37,545,200 | $37,759,400 | $37,441,900 | $36,086,800 | $34,369,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 705,500 | 789,500 | 497,300 | 561,700 | 671,300 |
| Accrued Expenses | N/A | N/A | N/A | 2,360,900 | 2,392,900 |
| Other current liabilities | 2,241,800 | 2,527,100 | 2,536,500 | N/A | N/A |
| TOTAL | $3,566,600 | $3,944,300 | $3,661,000 | $3,508,600 | $3,580,900 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,984,800 | 1,984,400 | 1,984,000 | 1,983,600 | 1,983,300 |
| Deferred Revenues | 619,300 | 627,700 | 627,200 | 586,000 | 516,700 |
| Other Non-Current Liabilities | 1,674,400 | 1,571,400 | 1,543,600 | 1,463,200 | 908,500 |
| TOTAL | $4,591,000 | $4,461,500 | $4,455,000 | $4,372,400 | $3,797,600 |
| Total Liabilities | $8,157,600 | $8,405,800 | $8,116,000 | $7,881,000 | $7,378,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 107,966 | 109,325 | 109,890 | 110,235 | 110,186 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 32,384,400 | 31,672,900 | 30,755,200 | 29,414,600 | 27,982,300 |
| Other shareholders' equity | 29,000 | -8,300 | 59,800 | -69,800 | -76,900 |
| TOTAL | $29,387,600 | $29,353,600 | $29,325,900 | $28,205,800 | $26,991,100 |
| Total Liabilities And Equity | $37,545,200 | $37,759,400 | $37,441,900 | $36,086,800 | $34,369,600 |